在法里西马布切换治疗不耐药的神经血管与年龄相关的黄斑退化现实世界的数据
Benjamin Ng1,2, Hema Kolli1, Naduviledeth Ajith Kumar1
1Birmingham and Midland Eye Centre, Dudley Road, Birmingham B18 7QH, UK.
Life (Basel, Switzerland)
|February 24, 2024
概括
转换法里西马布显示治疗不耐药的神经血管与年龄相关的黄斑变性 (nAMD) 的解剖学改善,但功能收益有限. 与之前的治疗相比,患者报告了法里西马布注射的积极经验.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经血管与年龄相关的黄斑变性 (nAMD) 构成了重大挑战,特别是在治疗不耐药的病例中.
- 法里西马布是一种新型双特异性抗体,为nAMD提供了一种新的治疗选择.
- 在对先前疗法耐药的患者中,评估转换为法里西马布是至关重要的.
研究的目的:
- 在治疗不耐药的nAMD中转换为faricimab后评估临床结果.
- 为了确定法里西马布治疗成功的预测因素.
- 为了记录患者报告的法里西马布注射的主观体验.
主要方法:
- 在英国第三级转诊单位转换为法里西马布的患者的回顾性病例审查.
- 对63只眼睛 (54名患者) 的临床和成像数据的分析,这些眼睛先前接受了抗VEGF治疗.
- 视力敏度,中央黄斑厚度 (CMT) 的评估,以及faricimab切换后患者报告的结果.
主要成果:
- 转换法里西马布导致了解剖学上的改善,89.1%的患者在第一剂后显示出改善的中央黄斑厚度 (CMT).
- 39.1%的患者实现了完全的视网膜干燥.
- 亚视网膜液预测了更好的功能结果,而初始CMT预测了解剖结果. 与之前的抗VEGF治疗相比,患者报告的副作用显著减少,例如浮动物和不适.
结论:
- 法里西马布在治疗不耐药的nAMD患者中显示了解剖疗效.
- 在这个队列中,使用法里西马布切换的功能改善似乎有限.
- 患者报告的结果表明,与以前的抗VEGF疗法相比,法里西马布的主观体验是有利的.
更多相关视频
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.0K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
1.1K
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:27Diabetic Retinopathy
55
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
55